Serina Therapeutics (SER) has shared an announcement.
Serina Therapeutics, Inc. has bolstered its executive team by appointing Dr. Srini Tenjarla as the new Senior Vice President of CMC & Formulation. With a rich background from Takeda Pharmaceuticals and prior experience at Shire Pharmaceuticals, Dr. Tenjarla brings a wealth of expertise in drug product development to oversee Serina’s expanding pipeline. His academic credentials include a Ph.D. in Pharmaceutical Sciences and a B.Sc. in Pharmacy, promising to enhance the company’s capacity in bringing new therapies to market.
Learn more about SER stock on TipRanks’ Stock Analysis page.